Milliman Contxt FAQ

Contxt is a modern SaaS platform designed to speed and standardize clinical trial pre-screening and enrollment by returning instant, interpreted real-world health data for individual participants.   

Contxt is used by organizations that are both responsible for trial enrollment performance and accountable for screen failures, enrollment variability, and the downstream cost of trial delays, including: 

• Patient recruitment companies seeking to reduce wasted effort, improve conversion quality, and differentiate in a commoditized market 

• CROs focused on enrollment predictability, compliance, and sponsor satisfaction 

• Site networks aiming to standardize pre-screening, reduce burden on coordinators, and improve throughput 

Contxt is designed for teams that need earlier, more consistent eligibility decisions and want to reduce manual workflows. 

Contxt is claims-first participant qualification for clinical trials. It brings rapid, interpreted participant health history into view within seconds, so enrollment teams can make better qualification decisions before time, site capacity, and sponsor trust are consumed. 

Contxt works alongside existing data sources and workflows (including EHR access and manual record retrieval), helping teams focus those resources where deeper validation is warranted. 

Many organizations still use EHR access and downstream record workflows; Contxt helps teams separate clear “no” decisions from likely qualifiers early—so time, site capacity, and record retrieval are focused where they matter most.

Traditional workflows often discover disqualifying factors late—after outreach, referral, site scheduling, and staff time have already been spent. That’s when screen failures become most expensive, and when delays ripple into sponsor ROI and timelines. 

Contxt reverses that sequence. By bringing eligibility-relevant insight forward to the top of the enrollment funnel, Contxt helps teams identify likely qualifiers and flag likely screen fails earlier, when leverage is highest and cost is lowest. 

With basic participant information and a HIPAA authorization, Contxt can return years of interpreted, structured prescription histories and medical claims data on nearly any U.S. individual.  

Claims data is especially useful early because it is structured and consistent, and it is often available earlier than designated record sets—making it well-suited for early triage and eligibility screening decisions.  

Yes. Contxt aligns to trial-specific inclusion and exclusion criteria and analyzes participant health data to surface qualification and disqualification factors, including contraindications or emerging risks that can remain hidden in fragmented manual workflows.  

This logic is informed by clinical expertise embedded in the product design—combining data science with clinical interpretation to ensure outputs reflect real-world enrollment decision-making. The team’s clinical disciplines include nurse, nurse practitioner, pharmacist, physician, and physician assistant. 

Contxt is built to return eligibility-relevant insight in seconds, enabling teams to use it in live workflows where speed matters, such as recruiter follow-up, rapid pre-screening, and prioritizing who should be referred to a site. 

Because Contxt operates early, value is realized quickly and compounds across the enrollment lifecycle—through fewer screen failures, less site burden, and faster progress toward milestones like first patient in (FPI). 

No. Contxt is designed to optimize existing recruitment and pre-screening workflows—improving the performance of your current systems, partners, and processes by ensuring fewer low-quality referrals enter the funnel. 

Contxt fits into recruitment and pre-screening workflows, helps inform whom to prioritize and whom to filter out, and can reduce rework and wasted spend across the funnel. Many organizations view Contxt as a qualification intelligence layer that makes downstream systems and partners perform better—because fewer low-quality referrals enter the system in the first place.  

Contxt helps reduce screen failures by identifying exclusion-triggering history earlier, before a candidate is referred to a site or moved deeper into screening workflows.  

This matters because screen failures aren’t just operational waste; they have direct economic consequences: 

• Lost site capacity and increased burden on coordinators 

• Delays to enrollment milestones and sponsor timelines 

• Erosion of sponsor trust (and future award probability) 

Contxt’s early filtering helps protect all three. 

When disqualifying signals and contraindications are missed, downstream risk increases—including protocol deviations and preventable adverse events. Contxt is designed to surface disqualifying factors and emerging risks earlier, helping teams validate continued participation and catch issues as they surface.  

In short: earlier clarity supports safer enrollment decisions, not just faster ones. 

Contxt requires a HIPAA-qualified authorization to return individually identifiable participant health data.  

More broadly, Contxt is backed by Milliman IntelliScript’s long history of secure, compliant data handling in regulated environments. This is extremely important for sponsors and vendors that demand explainability, audit readiness, and defensible processes.  

Yes. Recruitment is a game of volume, speed, discipline—and trust—especially when trial pipelines are volatile and teams must invest upfront without certainty of downstream revenue. 

Contxt helps teams screen and triage candidates quickly, identify likely screen fails earlier, and redirect those individuals to other opportunities where appropriate—reducing waste while preserving pipeline value. 

Acting early also matters because delays can increase participant drop-off risk, making fast, confident pre-screening critical to maintaining momentum. 

Yes. Contxt can be used to help screen inbound leads and cohorts early so teams can identify which candidates are most likely to qualify and where disqualifying factors may be present before expending heavy-touch effort.  

This supports smarter campaign launches, cleaner site referrals, and more predictable sponsor-facing delivery. 

Because Contxt operates at the top of the funnel, teams often see early improvements in: 

• Reduction in screen failures (fewer low-quality site referrals) 

• Time-to-qualification (faster eligibility answers) 

• Enrollment velocity (improved progress toward FPI and downstream milestones) 

• Site burden and cost (less coordinator time burned on false positives)  

• Sponsor satisfaction (more predictable enrollment delivery and fewer preventable issues) 

These gains compound across the trial lifecycle because every avoided screen fail saves time and money and preserves trust.  

Contxt’s value is measurable. Examples of outcomes organizations may document in case studies include: 

• First patient in achieved faster (e.g., weeks earlier) 

• Study closure achieved earlier (e.g., months earlier) 

• Meaningful screen fail reduction before site referral 

• Avoided screen fail cost savings and improved sponsor ROI 

A common starting point is a time-bound pilot with a live cohort (for example, a four-month pilot), designed to quantify: 

• Screen fail reduction 

• Enrollment acceleration 

• Avoided cost per study 

• Sponsor-ready evidence for renewal and expansion 

Because Contxt returns insight quickly, teams can benchmark impact early and make informed decisions about scaling across additional trials and partners. 

A successful pilot typically results in: 

• More consistent pre-screening decisions across teams 

• Earlier elimination of likely screen fails 

• Faster path to enrollment milestones 

• Stronger sponsor confidence (and repeatable proof) 

• Clear differentiation in a crowded recruitment market